IL134355A0 - Non-steroidal ligands for the estrogen receptor - Google Patents

Non-steroidal ligands for the estrogen receptor

Info

Publication number
IL134355A0
IL134355A0 IL13435597A IL13435597A IL134355A0 IL 134355 A0 IL134355 A0 IL 134355A0 IL 13435597 A IL13435597 A IL 13435597A IL 13435597 A IL13435597 A IL 13435597A IL 134355 A0 IL134355 A0 IL 134355A0
Authority
IL
Israel
Prior art keywords
estrogen receptor
steroidal ligands
steroidal
ligands
estrogen
Prior art date
Application number
IL13435597A
Other languages
English (en)
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of IL134355A0 publication Critical patent/IL134355A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/28—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/40—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/40—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/34—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/44—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/28—Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/548—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/794—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring
    • C07C49/796—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
IL13435597A 1994-04-25 1997-08-12 Non-steroidal ligands for the estrogen receptor IL134355A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/232,910 US5681835A (en) 1994-04-25 1994-04-25 Non-steroidal ligands for the estrogen receptor
PCT/US1997/013975 WO1999007668A1 (en) 1994-04-25 1997-08-12 Non-steroidal ligands for the estrogen receptor

Publications (1)

Publication Number Publication Date
IL134355A0 true IL134355A0 (en) 2001-04-30

Family

ID=26792695

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13435597A IL134355A0 (en) 1994-04-25 1997-08-12 Non-steroidal ligands for the estrogen receptor

Country Status (23)

Country Link
US (5) US5681835A (de)
JP (1) JP4417548B2 (de)
AT (1) AT500422B1 (de)
AU (1) AU4147297A (de)
BR (1) BR9714820A (de)
CA (1) CA2301189C (de)
CH (1) CH694250A5 (de)
CZ (1) CZ301729B6 (de)
DE (2) DE19782294T1 (de)
DK (1) DK200000198A (de)
EE (1) EE200000070A (de)
FI (1) FI20000294L (de)
GB (1) GB2344589B (de)
IL (1) IL134355A0 (de)
LU (1) LU90525B1 (de)
LV (1) LV12515B (de)
NO (1) NO20000657D0 (de)
NZ (1) NZ502625A (de)
RO (1) RO121849B1 (de)
SE (1) SE0000401L (de)
SI (1) SI20268A (de)
UA (1) UA65580C2 (de)
WO (1) WO1999007668A1 (de)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0710116B1 (de) 1993-05-13 2008-09-03 Poniard Pharmaceuticals, Inc. Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
ES2186511A1 (es) * 1997-08-12 2003-05-01 Glaxo Wellcome Inc Ligandos no esteroideos para receptor de estrogenos.
CZ300929B6 (cs) * 1997-08-15 2009-09-16 Duke University Sloucenina pro použití pri lécení nebo prevenci estrogenem stimulované rakoviny
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
US5990100A (en) * 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
US6417394B2 (en) * 2000-04-05 2002-07-09 Bristol Myers Squibb Pharma Company Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
WO2002014850A1 (en) * 2000-08-11 2002-02-21 Ionics, Incorporated A process and device for continuous ionic monitoring of aqueous solutions
EP1512413A3 (de) 2001-01-16 2009-09-23 Glaxo Group Limited Pharmazeutische Mischung gegen Krebs, die ein 4-Chinazolinamin in Kombination mit einem anderen antineoplastischen Wirkstoff enthält
US6599921B2 (en) 2001-02-22 2003-07-29 Nanodesign, Inc. Non-steroidal estrogen receptor ligands
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
AU2002309919B2 (en) * 2001-05-16 2008-04-10 Barr Laboratories, Inc. Treatment of conditions relating to hormone deficiencies by administration of progestins
AU2002323098A1 (en) * 2001-08-11 2003-03-03 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
CA2515174A1 (en) 2003-02-04 2004-08-19 Kabushiki Kaisha Yakult Honsha Breast cancer resistance protein (bcrp) inhibitor
US20040248989A1 (en) * 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US7196119B2 (en) 2003-10-21 2007-03-27 The Regents Of The University Of California Development of new selective estrogen receptor modulators
CA2652783C (en) * 2006-05-22 2015-07-14 Hormos Medical Ltd. Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
KR101510646B1 (ko) * 2007-02-14 2015-04-10 호르모스 메디칼 리미티드 치료적으로 유용한 트리페닐부텐 유도체의 제조 방법
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
CN101888841B (zh) * 2007-10-09 2012-09-26 宾夕法尼亚大学理事会 血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞
BRPI0818637A2 (pt) 2007-10-16 2015-04-07 Repros Therapeutics Inc Métodos de tratamento de sintoma da síndrome metabólica, de glicose em jejum prejudicada, da síndrome metabólica e de redução de níveis de glicose em, jejum em sujeito com hipogonadismo hipogonadotrófico secundário ou idiopático
US20090215733A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake
US8697685B2 (en) 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
MY161598A (en) 2009-01-30 2017-04-28 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US8410095B2 (en) 2009-05-20 2013-04-02 Glaxosmithkline Llc Thiazolopyrimidinone derivatives as PI3 kinase inhibitors
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
SI2467140T1 (sl) 2009-08-21 2016-10-28 Novartis Ag Lapatinib za zdravljenje raka
JP2013503178A (ja) 2009-08-26 2013-01-31 サイリーン ファーマシューティカルズ インコーポレーティッド タンパク質キナーゼ調節物質としての縮合キノリン
EP2477987B1 (de) 2009-09-14 2018-01-10 Gilead Sciences, Inc. Modulatoren des toll-like-rezeptors
DK3560498T3 (da) 2009-10-16 2022-11-14 Novartis Ag Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer
CN102666541B (zh) 2009-10-22 2015-11-25 吉里德科学公司 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物
BR112012024380A2 (pt) 2010-03-25 2015-09-15 Glaxosmithkline Llc compostos químicos
BR112012031464A2 (pt) 2010-06-10 2020-08-04 Aragon Pharmaceuticals, Inc. moduladores do receptor de estrogênio e os seus usos
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
US20130172378A1 (en) 2010-09-14 2013-07-04 Glaxosmithkline Llc Combination of BRAF and VEGF Inhibitors
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EP3170813B1 (de) 2010-10-06 2018-12-12 GlaxoSmithKline LLC Benzimidazol-derivate als pi3-kinase-hemmer
GB201112607D0 (en) 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
AU2012205601B2 (en) 2011-01-11 2016-03-24 Novartis Ag Combination
CN103613541B (zh) * 2011-01-28 2015-09-23 中国科学院大连化学物理研究所 一种四取代烯烃及其吡唑衍生物的制备方法
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
WO2013011153A2 (en) 2011-07-21 2013-01-24 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Method for the prognosis and treatment of metastasis in breast cancer
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
EP2797889A4 (de) * 2011-12-30 2015-06-03 Centaurus Biopharma Co Ltd Neuartige arylalkenderivate und deren verwendung als selektive östrogenrezeptormodulatoren
KR20140117644A (ko) 2012-01-31 2014-10-07 스미스클라인 비이참 (코르크) 리미티드 암을 치료하는 방법
EP2819676B1 (de) 2012-02-29 2018-05-30 Repros Therapeutics Inc. Kombinationstherapie zur behandlung von androgenmangel
EA201491530A1 (ru) 2012-03-20 2015-07-30 Серагон Фармасьютикалс, Инк. Модуляторы рецепторов эстрогенов и их применение
WO2013143597A1 (en) 2012-03-29 2013-10-03 Glaxo Group Limited Demethylase enzymes inhibitors
EP2909164A1 (de) 2012-10-19 2015-08-26 Fermion Oy Verfahren zur herstellung von ospemifen
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
US20150328320A1 (en) 2012-11-30 2015-11-19 Glaxosmithkline Llc Novel Pharmaceutical Composition
KR20150103735A (ko) 2013-01-09 2015-09-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 조합물
US20150329524A1 (en) 2013-01-10 2015-11-19 Glaxosmithkline Intellectual Property (No.2) Limited Fatty acid synthase inhibitors
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
HK1216231A1 (zh) 2013-06-03 2016-10-28 Novartis Ag Anti-pd-l1抗体及mek抑制剂及/或braf抑制剂的混合物
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
MX2016004267A (es) 2013-10-01 2016-07-08 Novartis Ag Combinacion.
US20160235714A1 (en) 2013-10-01 2016-08-18 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
BR112016011222A2 (pt) 2013-12-12 2017-09-19 Novartis Ag Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
EP3111222A1 (de) 2014-02-26 2017-01-04 Glaxosmithkline Intellectual Property (No. 2) Limited Verfahren zur behandlung von krebspatienten mit reaktion auf ezh2-inhibitor gsk126
KR20160127754A (ko) 2014-03-12 2016-11-04 노파르티스 아게 Btk 억제제 및 akt 억제제를 포함하는 조합물
EP4035664A3 (de) 2014-03-28 2022-11-30 Duke University Behandlung von krebs unter verwendung von selektiven östrogenrezeptormodulatoren
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
EP4140485A1 (de) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulatoren von toll-like-rezeptoren zur behandlung von hiv
EA201790369A1 (ru) 2014-09-16 2017-10-31 Джилид Сайэнс, Инк. Твердые формы модулятора толл-подобного рецептора
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112018002436A2 (pt) 2015-08-04 2018-09-18 Glaxosmithkline Ip Dev Ltd tratamento de combinação de usos de métodos destes
EP3331918A1 (de) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen und verwendungen und verfahren dafür
EP3331917A1 (de) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen sowie verwendungen und verfahren davon
BR112018002520A2 (pt) 2015-08-06 2018-09-18 Glaxosmithkline Ip Dev Ltd Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
US11633382B2 (en) 2015-11-10 2023-04-25 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
EP4015537A1 (de) 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen und verwendungen und verfahren dafür
CA3006930A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
ES2781474T3 (es) 2016-04-07 2020-09-02 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
PE20181884A1 (es) 2016-04-07 2018-12-07 Glaxosmithkline Ip Dev Ltd Amidas heterociclicas utiles como moduladores de proteinas
WO2018013559A1 (en) 2016-07-12 2018-01-18 Accutar Biotechnology Inc. Novel compounds and uses thereof
WO2018015879A1 (en) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
US11649289B2 (en) 2016-08-04 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Anti-ICOS and anti-PD-1 antibody combination therapy
US20180072711A1 (en) 2016-09-15 2018-03-15 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
CN118834201A (zh) 2016-12-01 2024-10-25 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
WO2018100536A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
CA3049912A1 (en) 2017-01-26 2018-08-02 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
EP3582855A1 (de) 2017-02-15 2019-12-25 GlaxoSmithKline Intellectual Property Development Limited Kombinationstherapie zur behandlung von krebs
CN110831582B (zh) 2017-07-05 2023-08-11 诺华股份有限公司 药物组合物
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
TW201922721A (zh) 2017-09-07 2019-06-16 英商葛蘭素史克智慧財產發展有限公司 化學化合物
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
EP3692033A1 (de) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulatoren des stimulators von interferongenen (sting) zur verwendung bei der behandlung von hiv
CN111417630B (zh) 2017-10-05 2023-06-06 葛兰素史克知识产权开发有限公司 干扰素基因刺激因子(sting)的调节剂
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2020030570A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
WO2020030571A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
EP4342473A3 (de) 2018-11-30 2024-05-15 GlaxoSmithKline Intellectual Property Development Limited Verbindungen zur verwendung in der hiv-therapie
WO2020160375A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
CN114391015A (zh) 2019-05-16 2022-04-22 斯汀塞拉股份有限公司 苯并[b][1,8]萘啶乙酸衍生物和使用方法
CN114302875A (zh) 2019-05-16 2022-04-08 斯汀塞拉股份有限公司 氧代吖啶基乙酸衍生物及使用方法
MA56397A (fr) 2019-06-26 2022-05-04 Glaxosmithkline Ip Dev Ltd Protéines de liaison à l'il1rap
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
IL290789B2 (en) 2019-08-26 2025-09-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
US20230067202A1 (en) 2020-01-28 2023-03-02 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
KR20230069144A (ko) 2020-09-14 2023-05-18 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체의 표적화된 분해를 위한 화합물의 결정질 형태
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (de) * 1962-09-13
US3367856A (en) * 1963-02-07 1968-02-06 Dow Corning Rearrangement of arylsilanes
GB1029221A (en) * 1963-09-02 1966-05-11 Ici Ltd Triarylalkane derivatives
GB1079747A (en) * 1965-07-07 1967-08-16 Ici Ltd Alkene derivatives
US3637856A (en) * 1965-07-12 1972-01-25 Ici Ltd Trans-1-p-(dialkylaminoalkyl) phenyl-1 2-diphenyl-alk-1-enes and salts thereof
GB1128379A (en) * 1966-06-20 1968-09-25 Ici Ltd Novel alkene derivatives, process for the preparation thereof and compositions containing the same
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity
EP0002097B1 (de) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalken-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
US4206234A (en) * 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
ATE1418T1 (de) * 1979-05-15 1982-08-15 Imperial Chemical Industries Plc 1-hydrocarbyloxyphenyl-1.2-diphenylalkenderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzung.
HU178253B (en) * 1979-08-15 1982-04-28 Gyogyszerkutato Intezet Process for preparing 1,1,2-triphenyl-propane and -propane derivatives
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FI77839C (fi) * 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
CA1229604A (en) * 1984-02-14 1987-11-24 Lorne J. Brandes Aminoalkyl ethers of phenols as antiproliferative anticancer agents
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US4859695A (en) * 1986-06-10 1989-08-22 Merck & Co., Inc. Antiestrogen agents having anabolic activity in animals
CA1289570C (en) * 1986-06-16 1991-09-24 Tetsuji Asao 1,1,2-triaryl-1-alkene derivatives
DE3700005A1 (de) * 1987-01-02 1988-07-14 Elsbett L Kolbenmechanik und kinematik eines axialmotors
DE3736682A1 (de) * 1987-10-29 1989-05-11 Klinge Co Chem Pharm Fab Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
ATE130293T1 (de) * 1990-10-01 1995-12-15 Univ Texas Tamoxifenderivate mit hoher affinität und ihre verwendung.
EP0589039A1 (de) * 1991-04-30 1994-03-30 Asahi Kasei Kogyo Kabushiki Kaisha Triphenylethylenderivate und sie enthaltende pharmazeutische präparation
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5965551A (en) * 1996-02-21 1999-10-12 North Carolina State University Method of treating alopecia

Also Published As

Publication number Publication date
GB2344589A (en) 2000-06-14
FI20000294A7 (fi) 2000-02-11
AT500422A1 (de) 2005-12-15
SE0000401L (sv) 2000-04-05
US20030073671A1 (en) 2003-04-17
CA2301189A1 (en) 1999-02-18
BR9714820A (pt) 2000-08-22
AU4147297A (en) 1999-03-01
LV12515A (lv) 2000-07-20
UA65580C2 (en) 2004-04-15
JP2001513525A (ja) 2001-09-04
NZ502625A (en) 2002-04-26
EE200000070A (et) 2000-10-16
DK200000198A (da) 2000-02-09
LU90525B1 (de) 2000-02-29
NO20000657L (no) 2000-02-09
US5877219A (en) 1999-03-02
CZ2000509A3 (cs) 2000-06-14
DE19782294T1 (de) 2000-08-24
DE19782294B4 (de) 2007-01-18
HK1033126A1 (en) 2001-08-17
FI20000294L (fi) 2000-02-11
US6207716B1 (en) 2001-03-27
US5681835A (en) 1997-10-28
US20010053774A1 (en) 2001-12-20
SE0000401D0 (sv) 2000-02-09
RO121849B1 (ro) 2008-06-30
GB0005931D0 (en) 2000-05-03
GB2344589B (en) 2002-02-06
JP4417548B2 (ja) 2010-02-17
LV12515B (en) 2001-07-20
CH694250A5 (fr) 2004-10-15
WO1999007668A1 (en) 1999-02-18
SI20268A (sl) 2000-12-31
CZ301729B6 (cs) 2010-06-02
AT500422B1 (de) 2009-03-15
NO20000657D0 (no) 2000-02-09
CA2301189C (en) 2006-05-23

Similar Documents

Publication Publication Date Title
GB2344589B (en) Non-steroidal ligands for the estrogen receptor
AU1199600A (en) Estrogen receptor ligands
AU3934895A (en) 5-ht2 receptor ligands
ZA9510592B (en) Estrogen agonists
HUP9700636A3 (en) Novel estrogen receptor
EP1137940A4 (de) Verfahren zur identifizierung von liganden von nukleären rezeptoren
AU2248195A (en) Opiate receptor ligands
AU3991595A (en) Muscarinic receptor ligands
HUP9901579A3 (en) Antibodies specific for alpha-d-integrin
EP0773959A4 (de) Adrenergischer rezeptor
HU9601990D0 (en) Reflector for headight
AU4600296A (en) Opiate receptor ligands
HUP0002758A3 (en) Non-steroidal ligands for the estrogen receptor
GB9803062D0 (en) Estrogen receptor ligands
AU2002323722A1 (en) Non-Steroidal Ligands for the Estrogen Receptor
GB9425502D0 (en) Novel receptor
GB9711992D0 (en) Estrogen receptor ligands
GB9717346D0 (en) Estrogen receptor ligands
GB9803202D0 (en) Estrogen Receptor Ligands
GB9803061D0 (en) Estrogen receptor ligands
GB9815373D0 (en) Receptor ligands
KR0112034Y1 (en) Airating device for hydrophonics
KR0112033Y1 (en) Airating device for hydrophonics
KR970006538Y1 (en) Device for preventing oil-leakage
HU9401926D0 (en) Saddle for bicyces

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired